Phase 2 Sclerosis Clinical Trials
137 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 137 trials
Recruiting
Phase 2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 2
A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Chronic respiratory failureNon-invasive ventilationRespiratory Insufficiency+7 more
University of Pennsylvania48 enrolled3 locationsNCT07071935
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Corcept Therapeutics279 enrolled35 locationsNCT05407324
Recruiting
Phase 2
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Digital Ulcers in Systemic Sclerosis
Topadur Pharma AG15 enrolled6 locationsNCT06954597
Recruiting
Phase 2
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Multiple Sclerosis
ModernaTX, Inc.180 enrolled17 locationsNCT06735248
Recruiting
Phase 2
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
InsomniaMultiple Sclerosis
University of Kansas Medical Center70 enrolled1 locationNCT06428006
Recruiting
Phase 2
Tofersen in Non-SOD1 ALS
ALS (Amyotrophic Lateral Sclerosis)
Washington University School of Medicine30 enrolled2 locationsNCT07294144
Recruiting
Phase 2
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Amyotrophic Lateral Sclerosis(ALS)
PhenoNet, Inc.105 enrolled20 locationsNCT07142291
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Atherosclerosis
Genentech, Inc.162 enrolled11 locationsNCT07448038
Recruiting
Phase 2
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Multiple SclerosisMultiple Sclerosis Fatigue
Johns Hopkins University46 enrolled1 locationNCT06170970
Recruiting
Phase 2
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
Hoffmann-La Roche12 enrolled17 locationsNCT07161258
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled54 locationsNCT06782490
Recruiting
Phase 1Phase 2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Vector Y Therapeutics12 enrolled11 locationsNCT07287397
Recruiting
Phase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled128 locationsNCT06470048
Recruiting
Phase 2
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)30 enrolled1 locationNCT02784210
Recruiting
Phase 2
A Study of Ranolazine in ALS
Amyotrophic Lateral Sclerosis
Swathy Chandrashekhar, MBBS72 enrolled6 locationsNCT06527222
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled71 locationsNCT06500702
Recruiting
Phase 2
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Multiple SclerosisRRMSRelapsing Remitting MS
Ari Green40 enrolled1 locationNCT07510607
Recruiting
Phase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled6 locationsNCT07287670